Reminyl is prescribed to treat Alzheimer’s disease. It has also been prescribed to treat mild cognitive impairment, although it has not been approved by the FDA for such use. Reminyl is manufactured by Johnson & Johnson and was approved by the FDA in 2001. It has been approved in 69 countries for treatment of Alzheimer’s.
In two clinical trials, it was seen that patients using Reminyl had an increased risk of heart attack and stroke compared to patients who took a placebo. The trial lasted two year, and in that time, 15 patients taking Reminyl died—compared to five patients taking placebos who died during the time period. Most of these deaths were caused by heart attack or stroke.